NeuroSense Therapeutics, a clinical-stage biotechnology company, has announced the offering of 1,732,000 ordinary shares and pre-funded warrants to purchase up to 1,248,000 ordinary shares. The ordinary shares are priced at $1.50 each, while the pre-funded warrants are priced at $1.4999 each, just below the ordinary share price. The pre-funded warrants are immediately exercisable and may be exercised at any time until fully exercised. This offering is being conducted on a 'reasonable best efforts' basis, with A.G.P./Alliance Global Partners serving as the exclusive placement agent. The offering is related to the ordinary shares issuable upon the exercise of the pre-funded warrants sold. Concurrently, NeuroSense is also engaging in a private placement of ordinary warrants to purchase 2,980,000 ordinary...Show More

NeuroSense Therapeutics, a clinical-stage biotechnology company, has announced the offering of 1,732,000 ordinary shares and pre-funded warrants to purchase up to 1,248,000 ordinary shares. The ordinary shares are priced at $1.50 each, while the pre-funded warrants are priced at $1.4999 each, just below the ordinary share price. The pre-funded warrants are immediately exercisable and may be exercised at any time until fully exercised. This offering is being conducted on a 'reasonable best efforts' basis, with A.G.P./Alliance Global Partners serving as the exclusive placement agent. The offering is related to the ordinary shares issuable upon the exercise of the pre-funded warrants sold. Concurrently, NeuroSense is also engaging in a private placement of ordinary warrants to purchase 2,980,000 ordinary shares, exercisable immediately at $1.50 per share and expiring five years from issuance. The securities are being sold under a securities purchase agreement dated April 10, 2024. NeuroSense's ordinary shares and publicly-listed warrants are traded on the Nasdaq Capital Market under the symbols 'NRSN' and 'NRSNW,' respectively. The offering is expected to close on or about April 15, 2024.